Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Chronic Lymphocytic Leukaemia: Update Bulletin [May 2016]

Product Code:
596200566
Publication Date:
April 2016
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of Chronic Lymphocytic Leukaemia (CLL). Topics covered include expert opinions about the recent label expansion of AbbVie’s/J&Js Imbruvica to the front-line setting and the design of the pivotal RESONATE-2 study that led to its expanded approval. Experts also discuss the recent FDA safety alerts that have been issued for Gilead’s Zydelig and their implications for the future usage of the drug in CLL. With the FDA approval of Bcl-2 inhibitor AbbVie’s/Roche’s Venclexta in CLL, KOLs also reveal whether they believe this agent is a game-changer and offer their opinions on its future opportunities as it joins the CLL treatment algorithm.


Key Business Questions

  • With AbbVie’s/J&J’s Imbruvica’s (ibrutinib) label expanded to front-line CLL, how successful will the drug be in this setting?
  • How do experts view the design of the RESONATE-2 study that led to Imbruvica’s expanded approval?
  • Will Imbruvica retain its position in the CLL space, or be better suited in combination with other therapies?
  • Are the FDA safety alerts issued for Gilead’s Zydelig (idelalisib) likely to impede use of the drug in CLL?
  • What could be the long-term impact of the safety issues reported with Zydelig?
  • As AbbVie’s/Roche’s Venclexta (venetoclax) became the first BCL-2 inhibitor approved by the FDA, how do experts view the approval of this agent in CLL?
  • Is Venclexta considered a game-changer and if so, what are the future opportunities for the drug in CLL?



customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved